https://www.auriniapharma.com https://www.auriniapharma.com/company/about https://www.auriniapharma.com/company/management-team https://www.auriniapharma.com/company/board-of-directors https://www.auriniapharma.com/company/responsibility https://www.auriniapharma.com/science/pipeline https://www.auriniapharma.com/science/aritinercept https://www.auriniapharma.com/science/lupus-nephritis https://www.auriniapharma.com/patients/resources https://www.auriniapharma.com/investors https://www.auriniapharma.com/news https://www.auriniapharma.com/science/lupkynis https://www.auriniapharma.com/science/scientific-publications https://www.auriniapharma.com/company/careers https://www.auriniapharma.com/company/contact https://www.auriniapharma.com/policies/privacy https://www.auriniapharma.com/policies/terms-of-use https://www.auriniapharma.com/policies/data-privacy-opt-out https://www.auriniapharma.com/policies/data-subject-request https://www.auriniapharma.com/prescribing-information-lukynis https://www.auriniapharma.com/prescribing-information-lukynis-spanish https://www.auriniapharma.com/medication-guide-lupkynis-spanish https://www.auriniapharma.com/medication-guide-lupkynis https://www.auriniapharma.com/press-releases/analysis-showing-lupkynis-r-is-a-cost-effective-treatment-for-lupus-nephritis-presented-at-national-kidney-foundations-spring-clinical-meeting-2024 https://www.auriniapharma.com/press-releases/aurinia-acquires-novel-pipeline-assets-targeting-autoimmune-and-kidney-related-diseases https://www.auriniapharma.com/press-releases/aurinia-addresses-dubious-proposals-put-forth-by-lucien-selce https://www.auriniapharma.com/press-releases/aurinia-and-lonza-announce-exclusive-agreement-for-dedicated-voclosporin-manufacturing-capacity https://www.auriniapharma.com/press-releases/aurinia-announces-2023-annual-general-meeting-results https://www.auriniapharma.com/press-releases/aurinia-announces-2024-annual-general-meeting-results https://www.auriniapharma.com/press-releases/aurinia-announces-addition-of-dr-brinda-balakrishnan-to-the-board-of-directors https://www.auriniapharma.com/press-releases/aurinia-announces-aurora-phase-3-clinical-data-for-voclosporin-in-lupus-nephritis-to-be-presented-at-national-kidney-foundation-2020-spring-clinical-meetings https://www.auriniapharma.com/press-releases/aurinia-announces-board-restructuring https://www.auriniapharma.com/press-releases/aurinia-announces-collaboration-and-licensing-agreement-with-otsuka-pharmaceutical-co-ltd-for-the-development-and-commercialization-of-voclosporin-in-europe-and-japan https://www.auriniapharma.com/press-releases/aurinia-announces-european-commission-approval-of-lupkynis-r-voclosporin-for-the-treatment-of-lupus-nephritis https://www.auriniapharma.com/press-releases/aurinia-announces-european-investigator-initiated-trial-to-evaluate-antiviral-activity-of-voclosporin-in-kidney-transplant-recipients-with-covid-19 https://www.auriniapharma.com/press-releases/aurinia-announces-first-participant-dosed-in-aur200-single-ascending-dose-trial https://www.auriniapharma.com/press-releases/aurinia-announces-japan-approval-of-lupkynis-r-voclosporin-to-treat-lupus-nephritis https://www.auriniapharma.com/press-releases/aurinia-announces-licensing-partner-otsuka-filed-initial-marketing-authorization-application-maa-for-voclosporin-with-the-european-medicines-agency-ema https://www.auriniapharma.com/press-releases/aurinia-announces-lupkynis-r-voclosporin-patent-challenge-settlement-reached-with-sun-pharmaceuticals https://www.auriniapharma.com/press-releases/aurinia-announces-management-transition https://www.auriniapharma.com/press-releases/aurinia-announces-new-employment-inducement-grant-under-nasdaq-listing-rule-5635-c-4 https://www.auriniapharma.com/press-releases/aurinia-announces-new-employment-inducement-grants-under-nasdaq-listing-rule-5635-c-4 https://www.auriniapharma.com/press-releases/aurinia-announces-new-employment-inducement-grants-under-nasdaq-listing-rule-5635-c-4-2 https://www.auriniapharma.com/press-releases/aurinia-announces-outcome-of-audrey-tm-clinical-trial-in-dry-eye-syndrome https://www.auriniapharma.com/press-releases/aurinia-announces-positive-aurora-phase-3-trial-results-demonstrating-voclosporin-superiority-over-standard-of-care-in-lupus-nephritis https://www.auriniapharma.com/press-releases/aurinia-announces-positive-chmp-opinion-for-lupkynis-r-voclosporin-for-the-treatment-of-adults-with-active-lupus-nephritis-in-europe https://www.auriniapharma.com/press-releases/aurinia-announces-positive-cost-effectiveness-assessment-of-lupkynis-tm-voclosporin-in-latest-icer-draft-evidence-report https://www.auriniapharma.com/press-releases/aurinia-announces-positive-results-from-phase-1-study-of-aritinercept-aur200 https://www.auriniapharma.com/press-releases/aurinia-announces-positive-topline-results-from-the-aurora-2-continuation-study-of-lupkynis-tm-voclosporin-for-the-treatment-of-adults-with-active-lupus-nephritis-ln https://www.auriniapharma.com/press-releases/aurinia-announces-ptab-has-terminated-inter-partes-review https://www.auriniapharma.com/press-releases/aurinia-announces-public-offering-of-common-shares https://www.auriniapharma.com/press-releases/aurinia-announces-publication-of-aurora-1-phase-3-study-results-with-lupkynis-tm-voclosporin-in-the-lancet https://www.auriniapharma.com/press-releases/aurinia-announces-results-of-annual-general-meeting https://www.auriniapharma.com/press-releases/aurinia-announces-results-of-the-2021-annual-general-meeting https://www.auriniapharma.com/press-releases/aurinia-announces-the-addition-of-three-seasoned-executive-leaders-to-advance-company-strategy-and-performance https://www.auriniapharma.com/press-releases/aurinia-announces-the-great-britain-marketing-authorization-of-lupkynis-r-voclosporin-for-the-treatment-of-lupus-nephritis https://www.auriniapharma.com/press-releases/aurinia-announces-u-s-food-and-drug-administration-acceptance-of-the-filing-of-new-drug-application-and-priority-review-for-voclosporin-for-the-treatment-of-lupus-nephritis https://www.auriniapharma.com/press-releases/aurinia-announces-upcoming-presentations-of-new-data-on-lupkynis-r-at-american-college-of-rheumatology-convergence-and-american-society-of-nephrology-kidney-week-2025 https://www.auriniapharma.com/press-releases/aurinia-announces-updated-interim-results-from-the-aurora-2-continuation-study-of-lupkynis-voclosporin-for-the-treatment-of-lupus-nephritis https://www.auriniapharma.com/press-releases/aurinia-announces-updates-to-the-board-of-directors https://www.auriniapharma.com/press-releases/aurinia-announces-year-two-commitment-to-patient-navigation-grant-program-to-address-barriers-for-individuals-living-with-lupus-and-lupus-nephritis https://www.auriniapharma.com/press-releases/aurinia-appoints-industry-veteran-timothy-p-walbert-to-its-board-of-directors https://www.auriniapharma.com/press-releases/aurinia-appoints-joe-miller-as-chief-financial-officer https://www.auriniapharma.com/press-releases/aurinia-appoints-max-colao-as-chief-commercial-officer-and-expands-u-s-commercial-leadership-team https://www.auriniapharma.com/press-releases/aurinia-appoints-two-new-board-directors-with-deep-experience-in-biopharma-leadership-commercial-strategy-mergers-and-acquisitions-and-advancing-therapeutic-pipelines https://www.auriniapharma.com/press-releases/aurinia-awards-250-000-in-grants-to-support-patient-navigation-programs https://www.auriniapharma.com/press-releases/aurinia-board-of-directors-announces-exploration-of-strategic-alternatives-to-maximize-shareholder-value https://www.auriniapharma.com/press-releases/aurinia-board-of-directors-appoints-dr-robert-t-foster-as-new-board-director-and-enters-cooperation-agreement-with-shareholder-mkt-capital https://www.auriniapharma.com/press-releases/aurinia-closes-us-191-7-million-public-offering-of-common-shares-and-full-exercise-of-underwriters-option-to-purchase-additional-common-shares https://www.auriniapharma.com/press-releases/aurinia-closes-us-200-million-public-offering-of-common-shares https://www.auriniapharma.com/press-releases/aurinia-commends-2024-updated-acr-guidelines-for-screening-treatment-and-management-of-lupus-nephritis https://www.auriniapharma.com/press-releases/aurinia-completes-final-patient-treatment-in-audrey-phase-2-3-clinical-trial-of-voclosporin-ophthalmic-solution-for-dry-eye-syndrome https://www.auriniapharma.com/press-releases/aurinia-completes-patient-enrollment-into-the-audrey-phase-2-3-clinical-trial-of-voclosporin-ophthalmic-solution-for-the-treatment-of-dry-eye-syndrome https://www.auriniapharma.com/press-releases/aurinia-completes-submission-of-new-drug-application-to-the-u-s-food-drug-administration-for-voclosporin-for-the-treatment-of-lupus-nephritis https://www.auriniapharma.com/press-releases/aurinia-completes-voclosporin-drug-drug-interaction-study-demonstrating-no-clinically-significant-interaction-with-mycophenolate-mofetil https://www.auriniapharma.com/press-releases/aurinia-discloses-2023-year-end-financial-and-operational-results-announces-corporate-actions-focused-on-enhancing-shareholder-value https://www.auriniapharma.com/press-releases/aurinia-files-form-s-8-to-register-shares-underlying-previously-disclosed-inducement-awards-for-newly-hired-employees https://www.auriniapharma.com/press-releases/aurinia-launches-campaign-aimed-at-educating-and-motivating-people-with-lupus-nephritis-to-prioritize-their-kidney-health-and-take-action https://www.auriniapharma.com/press-releases/aurinia-launches-resource-kit-for-people-living-with-lupus-nephritis-and-partners-with-national-kidney-foundation-on-awareness-initiative https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-announces-allowance-of-a-new-and-refined-method-of-use-patent-for-lupkynis-r-in-the-treatment-of-lupus-nephritis-from-the-united-states-patent-and-trademark-office https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-announces-collaboration-partner-otsuka-filed-new-drug-application-nda-for-lupkynis-r-voclosporin-in-japan https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-announces-delisting-from-the-toronto-stock-exchange https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-announces-kidney-biopsies-sub-study-data-from-the-lupkynis-r-voclosporin-aurora-2-clinical-trial-presented-at-congress-of-clinical-rheumatology-east-conference https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-announces-launch-of-lupus-nephritis-disease-state-awareness-initiative-for-healthcare-professionals-timeisnephrons-com https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-announces-new-and-refined-method-of-use-patent-for-lupkynis-r-in-the-treatment-of-lupus-nephritis-issued-by-united-states-patent-and-trademark-office https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-announces-nice-recommendation-of-lupkynis-r-voclosporin-for-adults-with-active-lupus-nephritis https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-announces-presentations-at-american-college-of-rheumatology-acr-convergence-2022 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-announces-presentations-at-american-society-of-nephrology-asn-kidney-week-2022 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-announces-presentations-at-american-society-of-nephrology-asn-kidney-week-2023-and-2023-american-college-of-rheumatology-convergence-acr https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-announces-presentations-at-the-2022-era-congress-and-the-2022-eular-congress https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-announces-presentations-at-the-2022-national-kidney-foundation-spring-clinical-meetings https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-announces-promising-topline-data-from-renal-biopsy-sub-study-of-the-aurora-trial https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-announces-swissmedic-approval-of-lupkynis-r-voclosporin https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-appoints-craig-johnson-to-board-of-directors-to-support-next-phase-of-growth https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-establishes-u-s-commercial-operations-center-in-rockville-maryland https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-initiates-rolling-submission-of-a-new-drug-application-to-the-u-s-food-and-drug-administration-for-voclosporin-in-the-treatment-of-lupus-nephritis https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-reports-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provides-update-on-recent-business-progress https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-reports-financial-results-for-the-three-and-six-months-ended-june-30-2025 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-reports-financial-results-for-the-three-and-twelve-months-ended-december-31-2024-and-provides-update-on-recent-corporate-progress https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-reports-financial-results-for-the-three-and-twelve-months-ended-december-31-2025-and-provides-update-on-recent-business-progress https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-reports-financial-results-for-the-three-months-ended-march-31-2025 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-reports-financial-results-for-the-three-months-ended-march-31-2026-and-provides-update-on-recent-business-progress https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-reports-first-quarter-2023-financial-and-operational-results https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-reports-first-quarter-2024-financial-and-operational-results https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-reports-second-quarter-and-six-months-2023-financial-and-operational-results https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-reports-second-quarter-and-six-months-2024-financial-and-operational-results https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-reports-third-quarter-and-nine-months-2023-financial-and-operational-results https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-reports-third-quarter-and-nine-months-2024-financial-and-operational-results-announces-strategic-restructuring-to-sharpen-focus-on-continued-lupkynis-r-growth-and-aur200-development https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-acquire-kezar-life-sciences-for-6-955-in-cash-per-share-plus-a-contingent-value-right https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-host-conference-call-to-discuss-aur200-phase-1-study-results-on-june-30-2025 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-participate-in-h-c-wainwright-23rd-annual-global-investment-conference https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-2020-rbc-capital-markets-virtual-global-healthcare-conference https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-the-11th-annual-leerink-global-healthcare-conference https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-the-2020-jefferies-virtual-london-healthcare-conference https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-the-2021-jefferies-london-healthcare-conference https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conference https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-the-bloom-burton-co-healthcare-investor-conference https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-the-btig-virtual-biotech-conference https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-the-btig-virtual-biotechnology-conference https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference-2 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-the-svb-leerink-10th-annual-global-healthcare-conference https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-three-upcoming-march-investor-conferences https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-three-upcoming-virtual-investor-conferences https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-two-upcoming-virtual-healthcare-conferences https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-upcoming-41st-annual-j-p-morgan-healthcare-conference https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-upcoming-investor-conferences https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-upcoming-investor-healthcare-conference https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-upcoming-january-investor-conferences https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-at-upcoming-september-investor-conferences https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-present-five-abstracts-at-asn-kidney-week-2021-and-acr-convergence-2021 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-2023-fourth-quarter-and-full-year-financial-and-operational-results-on-february-15-2024 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-2024-fourth-quarter-and-full-year-financial-and-operational-results-on-february-27-2025 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-first-quarter-2020-financial-results-on-may-14-2020 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-first-quarter-2021-financial-results-on-may-6-2021 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-first-quarter-2022-financial-and-operational-results-on-may-10-2022 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-first-quarter-2025-financial-and-operational-results-on-may-12-2025 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-first-quarter-financial-and-operational-results-on-may-2-2024 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-first-quarter-financial-and-operational-results-on-may-4-2023 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-fourth-quarter-and-full-year-2019-financial-results-on-march-5-2020 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-fourth-quarter-and-full-year-financial-and-operational-results-on-february-28-2023 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-fourth-quarter-and-year-end-2020-financial-results-on-february-24-2021 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-fourth-quarter-and-year-end-2021-financial-results-on-february-28-2022 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-second-quarter-2021-financial-results-on-august-5-2021 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-second-quarter-2022-financial-and-operational-results-on-august-4-2022 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-second-quarter-2025-financial-and-operational-results-on-july-31-2025 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-second-quarter-financial-and-operational-results-on-august-1-2024 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-second-quarter-financial-and-operational-results-on-august-3-2023 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-third-quarter-2019-financial-results-on-november-14-2019 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-third-quarter-2021-financial-results-on-november-3-2021 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-third-quarter-2022-financial-and-operational-results-on-november-3-2022 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-release-third-quarter-financial-and-operational-results-on-november-7-2024 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-nine-months-ended-september-30-2025-and-provide-update-on-recent-business-progress-on-november-4-2025 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-twelve-months-ended-december-31-2025-and-provide-update-on-recent-business-progress-on-february-26-2026 https://www.auriniapharma.com/press-releases/aurinia-pharmaceuticals-to-report-second-quarter-2020-financial-results-on-august-11-2020 https://www.auriniapharma.com/press-releases/aurinia-presents-additional-aurora-pivotal-trial-safety-data-at-the-era-edta-virtual-congress-2020 https://www.auriniapharma.com/press-releases/aurinia-presents-aurora-pivotal-trial-subgroup-analysis-at-the-eular-2020-e-congress https://www.auriniapharma.com/press-releases/aurinia-presents-breadth-of-data-at-asn-2023-demonstrating-clinical-importance-of-lupkynis-for-managing-lupus-nephritis https://www.auriniapharma.com/press-releases/aurinia-presents-breadth-of-data-from-aurora-clinical-program-underscoring-value-of-lupkynis-voclosporin-for-patients-with-lupus-nephritis-at-acr-2023 https://www.auriniapharma.com/press-releases/aurinia-presents-data-demonstrating-lupkynis-r-voclosporin-is-effective-in-achieving-proteinuria-treatment-targets-in-lupus-nephritis-defined-by-eular-era-recommendations https://www.auriniapharma.com/press-releases/aurinia-presents-data-demonstrating-lupkynis-tm-voclosporin-efficacy-across-lupus-nephritis-biopsy-classes-at-national-kidney-foundation-2021-spring-clinical-meetings https://www.auriniapharma.com/press-releases/aurinia-presents-data-reinforcing-lupkynis-r-safety-and-efficacy-for-people-with-lupus-nephritis-at-congress-of-clinical-rheumatology-east-2024 https://www.auriniapharma.com/press-releases/aurinia-presents-integrated-time-to-renal-response-data-from-the-aura-lv-and-aurora-trials-along-with-voclosporin-drug-drug-interaction-data-at-acr-convergence-2020 https://www.auriniapharma.com/press-releases/aurinia-presents-new-data-highlighting-real-world-utilization-and-value-of-lupkynis-r-in-treating-lupus-nephritis-at-american-society-of-nephrology-kidney-week-2024 https://www.auriniapharma.com/press-releases/aurinia-presents-new-data-underscoring-critical-importance-of-earlier-lupus-nephritis-detection-and-intervention-and-value-of-lupkynis-r-in-managing-ln-at-american-college-of-rheumatology-convergence-2024 https://www.auriniapharma.com/press-releases/aurinia-presents-results-from-the-two-year-aurora-2-continuation-study-at-the-2022-european-renal-association-era-congress https://www.auriniapharma.com/press-releases/aurinia-presents-safety-and-efficacy-profile-of-lupkynis-r-for-people-with-lupus-nephritis-at-european-alliance-of-associations-for-rheumatology-eular-congress-2024 https://www.auriniapharma.com/press-releases/aurinia-presents-voclosporin-efficacy-and-pharmacokinetic-data-from-integrated-analysis-of-aura-lv-and-aurora-pivotal-trials-at-asn-kidney-week-2020 https://www.auriniapharma.com/press-releases/aurinia-prices-us-166-7-million-public-offering-of-common-shares https://www.auriniapharma.com/press-releases/aurinia-prices-us-200-million-public-offering-of-common-shares https://www.auriniapharma.com/press-releases/aurinia-provides-preliminary-unaudited-fourth-quarter-and-full-year-2022-net-revenue-results https://www.auriniapharma.com/press-releases/aurinia-provides-preliminary-unaudited-fourth-quarter-and-full-year-2023-net-revenue-results https://www.auriniapharma.com/press-releases/aurinia-provides-update-on-proxy-statement https://www.auriniapharma.com/press-releases/aurinia-receives-exemptive-relief-from-canadian-securities-regulators-for-share-repurchase-program https://www.auriniapharma.com/press-releases/aurinia-reports-first-quarter-2019-financial-results-and-recent-operational-highlights https://www.auriniapharma.com/press-releases/aurinia-reports-first-quarter-2020-financial-results-and-recent-operational-highlights https://www.auriniapharma.com/press-releases/aurinia-reports-first-quarter-2021-financial-results-and-recent-operational-highlights https://www.auriniapharma.com/press-releases/aurinia-reports-first-quarter-2022-financial-and-operational-results https://www.auriniapharma.com/press-releases/aurinia-reports-first-quarter-financial-results-and-operational-highlights https://www.auriniapharma.com/press-releases/aurinia-reports-fourth-quarter-and-full-year-2017-financial-results-and-operational-highlights https://www.auriniapharma.com/press-releases/aurinia-reports-fourth-quarter-and-full-year-2018-financial-results-and-operational-highlights https://www.auriniapharma.com/press-releases/aurinia-reports-fourth-quarter-and-full-year-2019-financial-results-and-operational-highlights https://www.auriniapharma.com/press-releases/aurinia-reports-fourth-quarter-and-full-year-2020-financial-results-and-recent-operational-highlights https://www.auriniapharma.com/press-releases/aurinia-reports-fourth-quarter-and-full-year-2021-financial-results-and-company-updates https://www.auriniapharma.com/press-releases/aurinia-reports-fourth-quarter-and-full-year-2022-financial-results-and-company-updates https://www.auriniapharma.com/press-releases/aurinia-reports-new-inducement-grants-under-nasdaq-listing-rule-5635-c-4 https://www.auriniapharma.com/press-releases/aurinia-reports-new-inducement-grants-under-nasdaq-listing-rule-5635-c-4-2 https://www.auriniapharma.com/press-releases/aurinia-reports-new-inducement-grants-under-nasdaq-listing-rule-5635-c-4-3 https://www.auriniapharma.com/press-releases/aurinia-reports-new-inducement-grants-under-nasdaq-listing-rule-5635-c-4-4 https://www.auriniapharma.com/press-releases/aurinia-reports-new-inducement-grants-under-nasdaq-listing-rule-5635-c-4-5 https://www.auriniapharma.com/press-releases/aurinia-reports-new-inducement-grants-under-nasdaq-listing-rule-5635-c-4-6 https://www.auriniapharma.com/press-releases/aurinia-reports-new-inducement-grants-under-nasdaq-listing-rule-5635-c-4-7 https://www.auriniapharma.com/press-releases/aurinia-reports-new-inducement-grants-under-nasdaq-listing-rule-5635-c-4-8 https://www.auriniapharma.com/press-releases/aurinia-reports-new-inducement-grants-under-nasdaq-listing-rule-5635-c-4-9 https://www.auriniapharma.com/press-releases/aurinia-reports-second-quarter-2019-financial-results-and-operational-highlights https://www.auriniapharma.com/press-releases/aurinia-reports-second-quarter-2020-financial-results-and-recent-operational-highlights https://www.auriniapharma.com/press-releases/aurinia-reports-second-quarter-and-six-months-2021-financial-results-and-recent-operational-highlights https://www.auriniapharma.com/press-releases/aurinia-reports-second-quarter-and-six-months-2022-financial-and-operational-results https://www.auriniapharma.com/press-releases/aurinia-reports-second-quarter-financial-results-and-operational-highlights https://www.auriniapharma.com/press-releases/aurinia-reports-third-quarter-2019-financial-results-and-recent-operational-highlights https://www.auriniapharma.com/press-releases/aurinia-reports-third-quarter-2020-financial-results-and-recent-operational-highlights https://www.auriniapharma.com/press-releases/aurinia-reports-third-quarter-and-nine-months-2021-financial-results-and-company-updates https://www.auriniapharma.com/press-releases/aurinia-reports-third-quarter-and-nine-months-2022-financial-and-operational-results https://www.auriniapharma.com/press-releases/aurinia-reports-third-quarter-financial-results-clinical-highlights-and-corporate-development https://www.auriniapharma.com/press-releases/aurinia-responds-to-now-retracted-linkedin-post https://www.auriniapharma.com/press-releases/aurinia-response-in-support-of-2023-updated-eular-recommendations-for-management-of-lupus-and-new-treatment-paradigm-for-lupus-nephritis https://www.auriniapharma.com/press-releases/aurinia-showcases-three-oral-presentations-for-lupkynis-r-voclosporin-at-2023-european-renal-association-annual-meeting-in-milan-italy https://www.auriniapharma.com/press-releases/aurinia-submits-ind-application-to-us-food-drug-administration-for-aur-200 https://www.auriniapharma.com/press-releases/aurinia-to-participate-in-2024-cantor-fitzgerald-global-healthcare-conference https://www.auriniapharma.com/press-releases/aurinia-to-participate-in-h-c-wainwright-26th-annual-global-investment-conference https://www.auriniapharma.com/press-releases/aurinia-to-participate-in-jefferies-london-healthcare-conference https://www.auriniapharma.com/press-releases/aurinia-to-participate-in-upcoming-investor-healthcare-conferences https://www.auriniapharma.com/press-releases/aurinia-to-participate-in-upcoming-investor-healthcare-conferences-02-27 https://www.auriniapharma.com/press-releases/aurinia-to-present-preclinical-voclosporin-data-at-2020-keystone-symposia-conference https://www.auriniapharma.com/press-releases/aurinia-to-present-supportive-aurora-2-continuation-study-interim-analysis-demonstrating-long-term-safety-efficacy-of-lupkynis-tm-voclosporin-in-subjects-with-lupus-nephritis https://www.auriniapharma.com/press-releases/aurinia-underscores-enduring-commitment-to-people-living-with-lupus-nephritis-through-innovative-advocacy-and-education-initiatives-for-lupus-awareness-month https://www.auriniapharma.com/press-releases/aurinia-unveils-patient-navigation-grant-program-to-address-access-barriers-for-individuals-living-with-lupus-and-lupus-nephritis https://www.auriniapharma.com/press-releases/aurinia-will-attend-2024-jefferies-global-healthcare-conference https://www.auriniapharma.com/press-releases/aurinia-will-attend-2024-rbc-capital-markets-global-healthcare-conference https://www.auriniapharma.com/press-releases/correcting-and-replacing-aurinia-pharmaceuticals-to-release-third-quarter-financial-and-operational-results-on-november-2-2023 https://www.auriniapharma.com/press-releases/fda-approves-aurinia-pharmaceuticals-lupkynis-tm-voclosporin-for-adult-patients-with-active-lupus-nephritis https://www.auriniapharma.com/press-releases/glass-lewis-recommends-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-meeting https://www.auriniapharma.com/press-releases/glass-lewis-recommends-that-aurinia-shareholders-vote-for-all-proposals-at-2025-annual-general-meeting https://www.auriniapharma.com/press-releases/iss-joins-glass-lewis-in-recommending-aurinia-shareholders-vote-for-all-company-director-nominees-at-2023-annual-general-meeting https://www.auriniapharma.com/press-releases/iss-recommends-that-aurinia-shareholders-vote-for-all-proposals-at-2025-annual-general-meeting https://www.auriniapharma.com/press-releases/long-term-phase-3-data-published-in-arthritis-rheumatology-shows-lupkynis-r-voclosporin-preserved-kidney-function-up-to-three-years-in-lupus-nephritis-patients-with-no-new-or-unexpected-adverse-events https://www.auriniapharma.com/press-releases/new-aurora-1-analysis-lupkynis-based-triple-immunosuppressive-therapy-yields-deep-proteinuria-reduction-in-lupus-nephritis https://www.auriniapharma.com/press-releases/notice-of-new-dial-in-numbers-for-aurinia-pharmaceuticals-first-quarter-2022-financial-and-operational-results-on-may-10-2022 https://www.auriniapharma.com/press-releases/the-u-s-food-drug-administration-fda-approves-updated-lupkynis-r-voclosporin-label-to-include-long-term-data-from-the-aurora-clinical-program https://www.auriniapharma.com/press-releases/toni-braxton-and-aurinia-want-people-with-lupus-nephritis-to-get-uncomfortable-to-protect-their-kidneys https://www.auriniapharma.com/press-releases/update-new-aurinia-presentation-details-at-the-2024-bloom-burton-co-healthcare-investor-conference https://www.auriniapharma.com/aurinia-in-action/advocacy-team-supports-minority-health-month https://www.auriniapharma.com/aurinia-in-action/aurinia-launches-legislative-town-hall-series https://www.auriniapharma.com/aurinia-in-action/aurinia-team-members-celebrate-world-kidney-day https://www.auriniapharma.com/aurinia-in-action/breaking-barriers-and-inspiring-hope-in-autoimmune-disease-a-look-back-at-2023 https://www.auriniapharma.com/aurinia-in-action/driving-change-aurinia-awards-18-community-impact-grant-awards https://www.auriniapharma.com/aurinia-in-action/empowering-our-lupus-and-lupus-nephritis-community https://www.auriniapharma.com/aurinia-in-action/supporting-people-living-with-lupus-nephritis-by-putting-ln-in-focus https://www.auriniapharma.com/aurinia-in-action/the-strength-of-sisterhood-navigating-lupus-through-shared-resilience-and-self-advocacy